Argenica Therapeutics (ASX:AGN) Stroke Trial Update
✅ DSMB approves Phase 2 trial to proceed unchanged
✅ 86% of patients dosed, completion expected early Q2 2025

@ArgenicaT @Stew_Walters 

$AGN $AGN.ax #ASX #Biotech #ClinicalTrials #Argenica
#AGN #AGN.ax #ASX #Biotech #ClinicalTrials #Argenica